Chemomab Therapeutics Ltd 's Income per employee grew in the fourth quarter 2025 on a trailing twelve month basis to $ 749,583, the income was higher than average, indicating higher productivity of the company's employees. The Healthcare sector has seen employees of 25 other companies achieving higher income per employee. While income per employee total ranking has improved so far to 311, from total ranking in previous quarter at 354.
Chemomab Therapeutics Announces Closing of $10 Million Private Placement Recently, Chemomab Therapeutics Ltd announced the successful closing of a $10 million private placement financing round that included both new and existing top tier investors. This financing will extend the company s cash runway through the beginning of 2026, providing a boost to their operations and growth opportunities. Despite this positive development, there have been some concerning trends in the company s financial performance. In the fourth quarter of 2023, the income per employee at Chemomab Therapeutics Ltd fell on a trailing twelve month basis to $2,691,222. However, it s worth noting that despite this decrease, the productivity of the company s 9 employees remained above the company average.
In a move that underscores Chemomab Therapeutics commitment to its groundbreaking research and development activities, the biotech firm recently announced the successful completion of a $10 million Private Investment in Public Entity (PIPE) placement. This strategic financial move will significantly extend Chemomab s cash runway, ensuring sustainable operations well beyond the anticipated milestones in early 2025 and paving the way for groundbreaking breakthroughs in medical science and patient care. Extending Cash Runway for Groundbreaking Innovations: Chemomab Therapeutics, a leading biotechnology company dedicated to developing novel therapies for rare diseases, has successfully raised $10 million through a private placement offering. The PIPE placement will provide the company with substantial financial resources, enabling it to extend its cash runway until early 2026. This longer runway comes as a testament to Chemomab s commitment to pursuing breakthrough treatments and therapeutic options for patients requiring innovative solutions.
Companies with similar Income per Employee for 12 month ending Dec 31 2025, within Healthcare Sector
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
